Group A streptococcal vaccines: Facts versus fantasy

Current Opinion in Infectious Diseases

Volumn 22, Issue 6, 2009, Pages 544-552

  Steer, Andrew C ^a,b   Batzloff, Michael R ^c   Mulholland, Kim ^d,e   Carapetis, Jonathan R ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

M protein; Pharyngitis; Rheumatic fever; Streptococcus pyogenes; Vaccine

Indexed keywords

CYSTEINE PROTEINASE; FIBRONECTIN BINDING PROTEIN; M PROTEIN; STREPTOCOCCUS GROUP A VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

BACTERIUM PILUS; CLINICAL TRIAL; DRUG SAFETY; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; RHEUMATIC HEART DISEASE;

ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CLINICAL TRIALS AS TOPIC; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 70350557353     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328332bbfe     Document Type: Review

References (112)

1. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41:1114-1122.
2. Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A strepto-coccal vaccine: rationale, feasibility, and obstacles-report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 2005; 41:1150-1156.
3. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685-694.
4. O'Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007; 45:853-862
5. Pfoh E, Wessels MR, Goldmann D, Lee GM. Burden and economic cost of group A streptococcal pharyngitis. Pediatrics 2008; 121:229-234.
6. Bloomfield AL, Felty AR. Prophylactic vaccination against acute tonsillitis. John Hopkins Hosp Bull 1923; 34:251-253.
7. Swift HF. Intravenous vaccination with streptococci in rheumatic fever. J Assoc Am Physicians 1930; 45:247-259.
8. Wilson MG, Swift HF. Intravenous vaccination with hemolytic streptococci. Am J Dis Child 1931; 42:42-51.
9. Collis WRF, Sheldon W. Intravenous vaccines of haemolytic streptococci in acute rheumatism in childhood. Lancet 1932; 220:1261-1264.
10. Wasson VP. Immunization against rheumatic fever with hemolytic Streptococcus filtrate. Am Heart J 1938; 15:257-264.
11. Wasson VP. Immunization against rheumatic fever. J Pediatr 1943; 23: 24-30.
12. Wasson VP, Brown EE. Immunization against rheumatic fever with hemolytic Streptococcus filtrate. Am Heart J 1940; 20:1-11.
13. Wasson VP, Brown EE. Further studies in immunization against rheumatic fever. Am Heart J 1942; 23:291-305.
14. Veldee MV. Purification and precipitation of the erythrogenic factor of scarlet fever Streptococcus toxin and its antigenic value. Public Health Rep 1937; 52:819-829.
15. Veldee MV. A further study of the purification and tannic acid precipitation of scarlet fever toxin. Public Health Rep 1938; 53:909-913.
16. Veldee MV. The Dick reaction and scarlet fever morbidity following injections of a purified and tannic acid precipitated erythrogenic toxin. Public Health Rep 1941; 56:957-974.
17. Young DC. Failure of type specific Streptococcus pyogenes vaccines to prevent respiratory infections. Naval Med Bull 1946; 46:709-718.
18. Rantz LA. Group A hemolytic streptococcus antibodies. A study of the simultaneous infection of a large number of men by a single type. Arch Intern Med 1944; 73:238-240.
19. Schmidt WC. Type-specific antibody formation in man following injection of streptococcal M protein. J Infect Dis 1960; 106:250-255.
20. Potter EV, Stollerman GH, Siegel AC. Recall of type specific antibodies in man by injections of streptococcal cell walls. J Clin Invest 1962; 14:301-310.
21. Wolfe CK, Hayashi JA, Walsh G, Barkulis SS. Type-specific antibody reponse in man to injections of cell walls and M protein from group A, type 14 streptococci. J Lab Clin Med 1963; 61:459-468.
22. Massell BF, Michael JG, Amezcua J, Siner M. Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol 1968; 16:509-518.
23. Fox EN, Wittner MK, Dorfman A. Antigenicity of the M proteins of group A hemolytic streptococci III. Antibody responses and cutaneous hypersensitivity in humans. J Exp Med 1966; 124:1135-1151.
24. Fox EN, Waldman RH, Wittner MK, et al. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. J Clin Invest 1973; 52:1885-1892.
25. Polly SM, Waldman RH, High P, et al. Protective studies with a group A streptococcal M protein vaccine. II. Challenge of volunteers after local immunization in the upper respiratory tract. J Infect Dis 1975; 131:217-224.
26. D'Alessandri R, Plotkin G, Kluge RM, et al. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with type 3 or type 12 group A Streptococcus. J Infect Dis 1978; 138:712-718.
27. Beachey EH, Stollerman GH, Johnson RH, et al. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med 1979; 150:862-877.
28. Kotloff KL, Corretti M, Palmer K, et al. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA 2004; 292:709-715.
29. Fischetti VA, Windels M. Mapping the immunodeterminants of the complete streptococcal M6 protein molecule: identification of an immunodominant region. J Immunol 1988; 141:3592-3599.
30. Lancefield RC. Current knowledge of the type specific M antigens of group A streptococci. J Immunol 1962; 89:307-313.
31. Wannamaker LW, Denny FW, Perry WD, et al. Studies on immunity to streptococcal infections in man. AMA Am J Dis Child 1953; 86:347-348.
32. Lancefield RC. Persistence of type-specific antibodies in man following infection with group A streptococci. J Exp Med 1959; 110:271-292.
33. Dale JB, Chiang EC. Intranasal immunization with recombinant group A streptococcal M protein fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. J Infect Dis 1995; 171:1038-1041.
34. Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70:2171-2177.
35. Shulman ST, Tanz RR, Dale JB, et al. Seven-year surveillance of North American pediatric group A streptococcal pharyngitis isolates. Clin Infect Dis 2009; 49:78-84.
36. Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis. Lancet 2001; 358: 1334-1337.
37. Smeesters PR, Vergison A, Campos D, et al. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS One 2006; 1:e10.
38. Steer AC, Magor G, Jenney AWJ, et al. emm and C-repeat region molecular typing of beta-hemolytic streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009; 47:2502-2509.
39. Tewodros W, Kronvall G. M protein gene (emm-type) analysis of group A beta hemolytic streptococci from Ethiopia reveals unique patterns. J Clin Microbiol 2005; 43:4369-4376.
40. Bessen D, Fischetti VA. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. J Immunol 1990; 145: 1251-1256.
41. Guilherme L, Fae KC, Higa F, et al. Towards a vaccine against rheumatic fever. Clin Develop Immunol 2006; 13:125-132.
42. Guilherme L, Postol E, Freschi de Barros S, et al. A vaccine against S. pyogenes: design and experimental immune response. Methods 2009 [Epub ahead of print].
43. Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A Streptococcus by immunization with J8-diptheria toxoid: contribution of J8-and diptheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187:1598-1608.
44. Jones KF, Fischetti VA. The importance of the location of antibody binding on the M6 protein for opsonization and phagocytosis of group A M6 streptococci. J Exp Med 1988; 167:111 4-1123.
45. McArthur JD, Walker MJ. Domains of group A streptococcal M protein that confer resistance to phagocytosis, opsonization and protection: implications for vaccine development. Mol Microbiol 2006; 59:1-4.
46. Batzloff M, Yan H, Davies M, et al. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res 2004; 119 (Suppl):104-107.
47. Hayman WA, Brandt ER, Relf WA, et al. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of the group A Streptococcus. Int Immunol 1997; 9:1723-1733.
48. Pandey M, Batzloff MR, Good MF. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One 2009; 4:e5147.
49. Brandt ER, Hayman WA, Currie BJ, et al. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 1997; 15:1805-1812.
50. Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine 2002; 20:2816-2825.
51. Batzloff MR, Hartas J, Zeng W, et al. Intranasal vaccination with alipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A Streptococcus challenge and reduces throat colonization. J Infect Dis 2006; 194:325-330.
52. Batzloff MR, Yan H, Davies MR, et al. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group A Streptococcus. J Infect Dis 2005; 192:1450-1455.
53. Brandt E, Hayman W, Currie B, et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M-protein of group A streptococci. Immunology 1996; 89:331-337.
54. Guilherme L, Kalil J, Cunningham MW. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006; 39:31-39. (Pubitemid 43878518)
55. Park H-S, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005; 73:7878-7886.
56. Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A 1985; 82:8144-8148.
57. Cleary PP, Matsuka YV, Huynh T, et al. Immunization with C5a peptidase from either group A or group B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 2004; 22:4332-4341.
58. Ji Y, Carlson B, Kondagunta A, Cleary P. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 1997; 65:2080-2087.
59. O'Connor SP, Darip D, Fraley K, et al. The human antibody response to streptococcal C5a peptidase. J Infect Dis 1991; 163:109-116
60. Shet A, Kaplan EL, Johnson DR, Cleary PP. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 2003; 188:809-817.
61. Chmouryguina I, Suvorov A, Ferrieri P, Cleary PP. Conservation of the C5a peptidase genes in group A and B streptococci. Infect Immun 1996; 64:2387-2390.
62. Lancefield RC. The antigenic complex of Streptococcus hemolyticus. I. Demonstration of a type-specific substance in extracts of Streptococcus hemolyticus. J Exp Med 1928; 47:9-10.
63. Karakawa WW, Osterland CK, Krause RM. Detection of group specific antibodies in human sera. J Exp Med 1965; 121:793-806.
64. Salvadori LG, Blake MS, McCarty M, et al. Group A Streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J Infect Dis 1995; 171:593-600.
65. Zabriskie JB, Poon-King T, Blake MS, et al. Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. Adv Exp Med Biol 1997; 418:917-919.
66. Sabharwal H, Michon F, Nelson D, et al. Group A Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 2006; 193:129-135.
67. Schulze K, Medina E, Guzman CA. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine 2006; 24:1446-1450.
68. Kawabata S, Kunitomo E, Terao Y, et al. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice. Infect Immun 2001; 69:924-930.
69. Guzmán CA, Talay SR, Molinari G, et al. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibro-nectin-binding protein SfbI. J Infect Dis 1999; 179:901-906.
70. McArthur J, Medina E, Mueller A, et al. Intranasal vaccination with strepto-coccal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect Immun 2004; 72:7342-7345.
71. Ma CQ, Li CH, Wang XR, et al. Similar ability of FbaA with M protein to elicit protective immunity against group A Streptococcus challenge in mice. Cell Mol Immunol 2009; 6:73-77.
72. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2:156-162
73. Hytö nen J, Haataja S, Gerlach D, et al. The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, laminin-binding and cysteine protease activity. Mol Microbiol 2001; 39:512-519.
74. Roggiani M, Stoehr JA, Olmsted SB, et al. Toxoids of streptococcal pyro-genic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun 2000; 68:5011-5017.
75. Saouda M, Wu W, Conran P, Boyle MD. Streptococcal pyrogenic exotoxin B enhances tissue damage initiated by other Streptococcus pyogenes products. J Infect Dis 2001; 184:723-731.
76. Ulrich RG. Vaccine based on a ubiquitous cysteinyl protease and strepto coccal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock. J Immune Based Ther Vaccines 2008; 6:8.
77. Falugi F, Zingaretti C, Pinto V, et al. Sequence variation in group A strepto-coccus pili and association of pilus backbone types with Lancefield T serotypes. J Infect Dis 2008; 198:1834-1841.
78. Margarit I, Rinaudo Cira D, Galeotti Cesira L, et al. Preventing bacterial infections with pilus-based vaccines: the group B Streptococcus paradigm. J Infect Dis 2009; 199:108-115.
79. Zagursky RJ, Anderson AS. Application of genomics in bacterial vaccine discovery: a decade in review. Curr Opin Pharmacol 2008; 8:632-638.
80. Cole JN, Henningham A, Gillen CM, et al. Human pathogenic streptococcal proteomics and vaccine development. Proteomics Clin Appl 2008; 2:387-410.
81. Rodrguez-Ortega MJ, Norais N, Bensi G, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24:191-197.
82. McMillan DJ, Batzloff MR, Browning CL, et al. Identification and assessment of new vaccine candidates for group A streptococcal infections. Vaccine 2004; 22:2783-2790.
83. McMillan DJ, Davies MR, Browning CL, et al. Prospecting for new group A streptococcal vaccine candidates. Indian J Med Res 2004; 119 (Suppl): 121-125.
84. Cole JN, Ramirez RD, Currie BJ, et al. Surface analyses and immune reactivities of major cell wall-associated proteins of group A Streptococcus. Infect Immun 2005; 73:3137-3146.
85. Liu M, Zhu H, Zhang J, Lei B. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Infect Immun 2007; 75:3651-3657.
86. Lei B, Liu M,ChesneyGL, Musser JM. Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. J Infect Dis 2004; 189:79-89.
87. Lei B, Liu M, Voyich JM, et al. Identification and characterization of HtsA, a second heme-binding protein made by Streptococcus pyogenes. Infect Immun 2003; 71:5962-5969.
88. Turner CE, Kurupati P, Wiles S, et al. Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine 2009; 27:4923-4929.
89. Fritzer A, Noiges B, Schweiger D, et al. Chemokine degradation by the group A streptococcal serine proteinase ScpC can be reconstituted in vitro and requires two separate domains. Biochem J 2009; 422:533-542.
90. Severin A, Nickbarg E, Wooters J, et al. Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 2007; 189:151 4-1522.
91. Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969; 207:1115-1119.
92. Massell BF. Rheumatic fever and streptococcal infection: unraveling the mysteries of a dread disease. Cambridge, MA: Harvard University Press, for the Francis A. Countway Library of Medicine; 1997. p. 264.
93. Guilherme L, Oshiro SE, Fae KC, et al. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001; 69:5345-5351.
94. Guilherme L, Ramasawmy R, Kalil J. Rheumatic fever and rheumatic heart disease: genetics and pathogenesis. Scand J Immunol 2007; 66:199-207.
95. Roberts S, Kosanke S, Terrence Dunn S, et al. Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis 2001; 183:507-511
96. Georgousakis MM, McMillan DJ, Batzloff MR, Sriprakash KS. Moving forward: a mucosal vaccine against group A Streptococcus. Expert Rev Vaccines 2009; 8:747-760.
97. Aziz MA, MidhaS, Waheed SM, BhatnagarR. Oral vaccines: new needs, new possibilities. Bioessays 2007; 29:691-694.
98. Bessen D, Fischetti VA. Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med 1988; 167:1945-1950.
99. Pichichero ME, Insel RA. Mucosal antibody response to parenteral vaccination with Haemophilus influenzae type b capsule. J Allergy Clin Immunol 1983; 72:481-486.
100. Fernandez J, Levine OS, Sanchez J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 2000; 182:1553-1556.
101. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113:163-174.
102. Simerska P, Abdel-Aal A-BM, Fujita Y, et al. Development of a liposaccharide-based delivery system and its application to the design of group A strepto-coccal vaccines. J Med Chem 2008; 51:1447-1452.
103. Simerska P, Abu-Baker MA-A, Fujita Y, et al. Synthesis and in vivo studies of carbohydrate-based vaccines against group A Streptococcus. Biopolymers 2008; 90:611-616.
104. Kotloff KL, Wasserman SS, Jones KF, et al. Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A Streptococcus vaccine. Infect Immun 2005; 73:2360-2366.
105. Carapetis JR, Walker AM, Hibble M, et al. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect 1999; 122:59-65.
106. Steer AC, Jenney AWJ, Kado J, et al. Invasive group A streptococcal disease in Fiji: prospective surveillance 2005-2007. Emerg Infect Dis 2009; 15: 216-222.
107. Ahn S-Y, Ingulli E. Acute poststreptococcal glomerulonephritis: an update. Curr Opin Pediatr 2008; 20:157-162.
108. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis 2004; 4:240-245.
109. McDonald MI, Towers RJ, Andrews RM, et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic feveris hyperendemic. Clin Infect Dis 2006; 43:683-689.
110. Kaplan EL, Bisno AL. Antecedent streptococcal infection in acute rheumatic fever. Clin Infect Dis 2006; 43:690-692.
111. Gerber MA, Tanz RR, Kabat W, et al. Potential mechanisms for failure to eradicate group A streptococci from the pharynx. Pediatrics 1999; 104:911-917.
112. Shulman ST, Gerber MA, Tanz RR, Markowitz M. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J 1994; 13:1-7.